Hua-Chen Chang
Overview
Explore the profile of Hua-Chen Chang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
1336
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Awe O, Hufford M, Wu H, Pham D, Chang H, Jabeen R, et al.
J Immunol
. 2015 Sep;
195(8):3705-15.
PMID: 26363052
PU.1 is an ETS family transcription factor that is important for the development of multiple hematopoietic cell lineages. Previous work demonstrated a critical role for PU.1 in promoting Th9 development...
2.
Yang X, Zhu J, Tung C, Gardiner G, Wang Q, Chang H, et al.
PLoS One
. 2015 Feb;
10(2):e0115330.
PMID: 25646897
Lunasin is a naturally occurring peptide isolated from soybeans and has been explored in cancer treatment. Lunasin inhibits NF-κB activation and thus pro-inflammatory cytokine and mediator production in macrophages. In...
3.
Voiles L, Lewis D, Han L, Lupov I, Lin T, Robertson M, et al.
Oncol Rep
. 2014 Sep;
32(5):1897-904.
PMID: 25176343
Type VI collagen (COL6), an extracellular matrix protein, is important in maintaining the integrity of lung tissue. An increase in COL6 mRNA and protein deposition was found in the lungs...
4.
Tung C, Lewis D, Han L, Jaja M, Yao S, Li F, et al.
Vaccine
. 2014 Aug;
32(42):5411-9.
PMID: 25131731
The addition of an appropriate adjuvant that activates the innate immunity is essential to subsequent development of the adaptive immunity specific to the vaccine antigens. Thus, any innovation capable of...
5.
Chang H, Lewis D, Tung C, Han L, Henriquez S, Voiles L, et al.
Cancer Immunol Immunother
. 2013 Dec;
63(3):283-95.
PMID: 24363024
Immunostimulatory cytokines can enhance anti-tumor immunity and are part of the therapeutic armamentarium for cancer treatment. We have previously reported that post-transplant lymphoma patients have an acquired deficiency of signal...
6.
Srivastava S, Pelloso D, Feng H, Voiles L, Lewis D, Haskova Z, et al.
Cancer Immunol Immunother
. 2013 Apr;
62(6):1073-82.
PMID: 23604103
The antitumor activity of monoclonal antibodies is mediated by effector cells, such as natural killer (NK) cells, that express Fc receptors for immunoglobulin. Efficacy of monoclonal antibodies, including the CD20...
7.
Lupov I, Voiles L, Han L, Schwartz A, De La Rosa M, Oza K, et al.
Blood
. 2011 Oct;
118(23):6097-106.
PMID: 21998209
Signal Transducer and Activator of Transcription 4 (STAT4) is a transcription factor that is activated by IL-12 signaling and promotes Th1-cell differentiation and IFN-γ production. Defective IFN-γ production because of...
8.
Jabeen R, Chang H, Goswami R, Nutt S, Kaplan M
PLoS One
. 2011 Jul;
6(7):e22189.
PMID: 21779390
Background: T cell development results in the generation of both mature αβ and γδ T cells. While αβ T cells predominate in secondary lymphoid organs, γδ T cells are more...
9.
Chang H, Sehra S, Goswami R, Yao W, Yu Q, Stritesky G, et al.
Nat Immunol
. 2010 May;
11(6):527-34.
PMID: 20431622
CD4(+) helper T cells acquire effector phenotypes that promote specialized inflammatory responses. We show that the ETS-family transcription factor PU.1 was required for the development of an interleukin 9 (IL-9)-secreting...
10.
Chang H, Han L, Jabeen R, Carotta S, Nutt S, Kaplan M
J Immunol
. 2009 Oct;
183(8):4887-94.
PMID: 19801513
The Ets transcription factor PU.1 is a master regulator for the development of multiple lineages during hematopoiesis. The expression pattern of PU.1 is dynamically regulated during early T lineage development...